EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

Joseph F Merola, Cynthia E Kartman, Peter Fischer, Philip Mease iD, Alan Kivitz, Naveed Sattar, Laura C Coates iD, Daniel Aletaha, Luna Sun, Yurong Chen, Ketan Marulkar, Natalia Bello und 3 weitere

Arthritis & Rheumatology · 11.11.2026

DOI: 10.1002/art.70375 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 11.11.2026. Verfasst von Joseph F Merola und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology and Medicine, Division of Rheumatology, and O'Donnell School of Public Health, University of Texas Southwestern Medical Ce…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight‐related comorbidity at the week 36 primary end point. The objective of this report is to evaluate the effect of IXE+TZP versus IXE on psoriatic disease control and safety measures up to week 52.

Methods

TOGETHER‐PsA ( ClinicalTrials.gov ID NCT06588296) is a phase 3b, randomized, open‐label, assessor‐blinded 52‐week trial. Participants were randomized 1:1 to IXE+TZP or IXE using US‐approved doses. Week 52 outcomes were prespecified, non–multiplicity‐controlled, and exploratory. Outcomes included 50% improvement in American College of Rheumatology response criteria (ACR50) and rheumatologic, dermatologic, patient‐reported, metabolic, and safety outcomes.

Results

A total of 271 participants were randomized (IXE+TZP, n = 138; IXE, n = 133). The proportion achieving the primary outcome of simultaneous ACR50 and ≥10% weight reduction continued to increase from week 36 through week 52 for IXE+TZP (39.2%) versus IXE (1.7%) (Δ37.5%; P < 0.001). ACR50 continued to diverge after week 36, with a clinically meaningful difference at week 52 for IXE+TZP (43.7%) versus IXE (15.7%) (Δ 28.0%; P < 0.001). IXE+TZP demonstrated significant improvements in ACR20, minimal disease activity, Disease Activity Index for Psoriatic Arthritis, patient‐reported outcomes, and metabolic outcomes versus IXE alone. Safety profiles were consistent with previous studies for each drug.

Conclusion

Comprehensive improvements in disease activity, including ACR50, quality of life, weight, and metabolic outcomes, continued through week 52 and were greater with IXE+TZP than IXE alone, with no new safety concerns. These findings support concomitant IXE+TZP in patients with active PsA and immunometabolic disease. image

Autor:innen und Institutionen

  • Departments of Dermatology and Medicine, Division of Rheumatology, and O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas.
  • Eli Lilly and Company, Indianapolis, Indiana.
  • Providence Swedish Medical Center and University of Washington, Seattle.
  • Altoona Center for Clinical Research, Duncansville, Pennsylvania.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Philip Mease, Laura C Coates

Förderung

  • Eli Lilly and Company

Zitieren

APA

Merola, J. F., Kartman, C. E., Fischer, P., Mease, P., Kivitz, A., Sattar, N., Coates, L. C., Aletaha, D., Sun, L., Chen, Y., Marulkar, K., Bello, N., Cardoso, A., Genovese, M. C., & Ogdie, A. (2026). Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.70375

Vancouver

Merola JF, Kartman CE, Fischer P, Mease P, Kivitz A, Sattar N, et al. Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial. Arthritis & Rheumatology. 2026. doi:10.1002/art.70375

BibTeX
@article{Merola2026,
  author = {Merola, Joseph F and Kartman, Cynthia E and Fischer, Peter and Mease, Philip and Kivitz, Alan and Sattar, Naveed and Coates, Laura C and Aletaha, Daniel and Sun, Luna and Chen, Yurong and Marulkar, Ketan and Bello, Natalia and Cardoso, Anabela and Genovese, Mark C and Ogdie, Alexis},
  title = {Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70375}
}
Kostenlos starten →